Plural Chalcogens Bonded Directly To The Hetero Ring Patents (Class 549/417)
-
Patent number: 8183398Abstract: Skin brightening compositions based on esters of 5-hydroxy-2-methyl-4H-pyran-4-one. Also disclosed are methods of making the compositions as well as methods of using the compositions.Type: GrantFiled: April 7, 2010Date of Patent: May 22, 2012Assignee: Eastman Chemical CompanyInventors: Michael Fitzpatrick Wempe, Jeffrey Michael Clauson, Liu Deng
-
Patent number: 8183397Abstract: The process for the synthesis of statins featuring the use of an early intermediate (4R,6S)-6-(dialkoxymethyl)tetrahydro-2H-pyran-2,4-diol which already possesses the desired stereochemistry corresponding to the final statin.Type: GrantFiled: April 2, 2008Date of Patent: May 22, 2012Assignee: Lek Pharmaceuticals D.D.Inventors: Zdenko Casar, Tomaz Mesar, Gregor Kopitar, Peter Mrak, Matej Oslaj
-
Patent number: 8178658Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.Type: GrantFiled: February 11, 2009Date of Patent: May 15, 2012Assignee: Dow AgroSciences, LLCInventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
-
Publication number: 20120029198Abstract: Esters of O-substituted hydroxy carboxylic acids are provided having Formula 1, or 2, or both Formulas 1 and 2: wherein R and R1 are independently selected from the group consisting of substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1-C22 alkyl, substituted and unsubstituted C3-C8 cycloalkyl, substituted and unsubstituted C6-C20 carbocyclic aryl, and substituted and unsubstituted C4-C20 heterocyclic; wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; and wherein n is 1-6. Process of producing esters of O-substituted hydroxy carboxylic acids are also provided.Type: ApplicationFiled: December 22, 2010Publication date: February 2, 2012Applicant: EASTMAN CHEMICAL COMPANYInventors: Liu Deng, Neil Warren Boaz
-
Publication number: 20120022251Abstract: The present invention provides a pyrone derivative and a pyridone derivative, which are novel intermediates for synthesizing an anti-influenza drug, a method of producing the same, and a method of using the same.Type: ApplicationFiled: March 26, 2010Publication date: January 26, 2012Inventors: Yukihito Sumino, Kazuya Okamoto, Moriyasu Masui, Toshiyuki Akiyama
-
Publication number: 20120021907Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.Type: ApplicationFiled: January 6, 2010Publication date: January 26, 2012Applicant: SYNGENTA CROP PROTECTION LLCInventors: Christopher John Mathews, John Finney, James Nicholas Scutt, Louisa Robinson, John Stephen Delaney
-
Publication number: 20120021909Abstract: Compounds of Formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.Type: ApplicationFiled: January 25, 2010Publication date: January 26, 2012Applicant: SYNGENTA CROP PROTECTION LLCInventors: Christopher John Mathews, John Finney, James Nicholas Scutt, Louisa Robinson, John Stephen Delaney
-
Publication number: 20110306778Abstract: The present invention provides a process for preparing a spiroketal derivative, via an intermediate represented by Formula (VI): wherein variable groups and numbers are as defined in the specification, which can be produced from dihalobenzene derivatives in one pot reaction.Type: ApplicationFiled: June 19, 2009Publication date: December 15, 2011Inventors: Masatoshi Murakata, Takuma Ikeda, Nobuaki Kimura, Akira Kawase, Masahiro Nagase, Keisuke Yamamoto
-
Publication number: 20110294903Abstract: A crystallized maltitol powder including a maltitol content greater than 99.5% by weight, characterized by a particle-size distribution by volume, determined by laser granulometry, having less than 20% particles less than 200 ?m in size, less than 6% particles less than 100 ?m in size, less than 2% particles less than 40 ?m in size and a pour value less than or equal to 10 seconds, an aerated density greater than 0.85 g/ml, a compacted density greater than 0.97 g/ml, and a compressibility of less than 17%, and to its use in the pharmaceuticals and above all foods sectors, in particular in the formulation of chocolates or table sweeteners.Type: ApplicationFiled: February 20, 2009Publication date: December 1, 2011Applicant: ROQUETTE FRERESInventors: Manuel Barata, Yves Le Bot, Elsa Muller née Ostermann, Guillaume Ribadeau-Dumas
-
Publication number: 20110281879Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: ApplicationFiled: January 12, 2011Publication date: November 17, 2011Applicant: ViroBay, Inc.Inventor: Craig Mossman
-
Publication number: 20110269713Abstract: Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compounds described herein can also treat memory loss. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in fewer steps and with a higher degree of substitution and specificity.Type: ApplicationFiled: October 14, 2010Publication date: November 3, 2011Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Gary E. Keck, Matthew B. Kraft, Anh P. Truong, Carina C. Sanchez, Wei Li, Jonathan A. Covel, Dennie Welch, Yam Poudel
-
Publication number: 20110263699Abstract: Metabolites of [2-(3-methoxyphenyl)-cyclohexylmethyl]dimethylamine as free bases and/or in the form of physiologically acceptable salts, corresponding medicaments, the use of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for producing a medicament used for treating depression, and related methods of treating depression, pain and urinary incontinence.Type: ApplicationFiled: July 1, 2011Publication date: October 27, 2011Applicant: GRUENENTHAL GmbHInventors: Elmar Friderichs, Wolfgang Strassburger, Ulrich Jahnel, Derek Saunders, Hagen-Heinrich Hennies, Werner Englberger, Helmut Buschmann, Joerg Holenz, Oswald Zimmer
-
Publication number: 20110245335Abstract: The present invention relates in general to a compound which is characterized by a formula selected from the following formulas A, B, C, D, E or F; or a pharmaceutically acceptable salt thereof. The present invention further relates to pharmaceutical composition comprising the inhibitor(s) of the invention and to their use in the treatment of (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer. The present invention furthermore relates to the use of at least one inhibitor of the invention for the preparation of a pharmaceutical composition for the treatment of (for treating) a disease which is associated with an excess transport of hyaluronan across a lipid bilayer. The present invention also relates to a method for manufacturing a pharmaceutical composition comprising the steps of formulating the inhibitor defined herein in a pharmaceutically acceptable form.Type: ApplicationFiled: December 14, 2009Publication date: October 6, 2011Inventor: Peter Prehm
-
Publication number: 20110245516Abstract: Novel processes and intermediates are provided according to the general reaction scheme: Formula I, II, III, IV (I), (II), (III), (IV) utilizing a ruthenium catalyst in an oxidative cleavage of the triene 4 whereby an aldehyde may be produced and optionally taken on to a carboxylic acid 5: Formula V (V)Type: ApplicationFiled: December 8, 2009Publication date: October 6, 2011Inventor: Yasunori Aoyama
-
Patent number: 8003689Abstract: This invention provides metabolites of SARM compounds including inter alia glucuronidated metabolites and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others.Type: GrantFiled: June 19, 2009Date of Patent: August 23, 2011Assignee: GTx, Inc.Inventor: Karen A. Veverka
-
Publication number: 20110190127Abstract: Pyranone, thiopyranone and cyclohexenedione compounds of formula (I), which are suitable for use as herbicides.Type: ApplicationFiled: June 4, 2009Publication date: August 4, 2011Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: James Nicholas Scutt, Christopher John Mathews
-
Publication number: 20110183940Abstract: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.Type: ApplicationFiled: July 23, 2009Publication date: July 28, 2011Inventors: Brian Alvin Johns, Jason Gordon Weatherhead, Toshikazu Hakogi, Yasunori Aoyama
-
Publication number: 20110178295Abstract: The process for the synthesis of statins featuring the use of an early intermediate (4R,6S)-6-(dialkoxymethyl)tetrahydro-2H-pyran-2,4-diol which already possesses the desired stereochemistry corresponding to the final statin.Type: ApplicationFiled: April 2, 2008Publication date: July 21, 2011Applicant: LEK PHARMACEUTICALS D.D.Inventors: Zdenko Casar, Tomaz Mesar, Gregor Kopitar, Peter Mrak, Matej Oslaj
-
Publication number: 20110152095Abstract: Pyrandione, thiopyrandione and cyclohexanetrione derivatives of formula (I), which are suitable for use as herbicides.Type: ApplicationFiled: June 4, 2009Publication date: June 23, 2011Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: James Nicholas Scutt, Christopher John Mathews, Michel Muehlebach
-
Patent number: 7955824Abstract: The invention provides novel compounds that may be used as intermediates in the preparation of epothilones, epothilone analogs and derivative, as well as new synthetic methods for producing the intermediates and products.Type: GrantFiled: May 9, 2008Date of Patent: June 7, 2011Assignee: Kosan Biosciences IncorporatedInventors: John R. Carney, Yong Li, Hugo Menzella, Ralph C. Reid
-
Publication number: 20110112184Abstract: Compounds of the general formula (I) and (II) (including formulae (III) to (V)), wherein X=—CH2—, —O—, —S— n=0-10 Y=—NH—, —NHSO2—, —NHSO—, —NHCO—, —S—, —O—, —CH?CH—R1-R7, equal or different can be hydrogen, alkyl C1-C4, alkenyl C2-C4, cycloalkyl C3-C7, aryl or heteroaryl; may be substituted with one or more alkyl C1-C4, alkoxyl C1-C4, alkylthio C1-C4 or halogens; —NR8R9, where R8 e R9, equal or different, represent hydrogen, alkyl C1-C4, alkenyl C2-C4, cycloalkyl C3-C7, aryl or heteroaryl, may be substituted with one or more C1-C4, alkoxyl C1-C4, alkylthio C1-C4 or halogens; —(CH2)n, —COOR10, with n?=0-4 and R3=hydrogen or alkyl C1-C4, and their addition salts with organic and inorganic acids, or alkaline and alkaline earth metal or ammonium ions, with the exclusion of the compounds having the following formulae ((VI) to (IX)).Type: ApplicationFiled: May 7, 2009Publication date: May 12, 2011Inventors: Barbara La Perla, Francesco Nicotra, Andrea Balsari, Marco Palazzo, Cristiano Rumio
-
Patent number: 7914862Abstract: A liquid crystal compound is provided that has excellent characteristics, such as a negatively large dielectric anisotropy. A liquid crystal composition containing the compound, and a liquid crystal display device containing the composition are also provided. A compound having the three factors, i.e., (1) a tetrahydropyran ring, (2) —CH2O— or —OCH2— and (3) exhibits excellent characteristics including a negatively large dielectric anisotropy. The use of the compound having the characteristics provides an excellent liquid crystal composition and an excellent liquid crystal display device.Type: GrantFiled: May 4, 2009Date of Patent: March 29, 2011Assignees: Chisso Corporation, Chisso Petrochemical CorporationInventor: Tokifumi Masukawa
-
Patent number: 7902384Abstract: The present invention relates to compounds having estrogenic activity selected from the group consisting of Loliolide, (4S,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one, (4R,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one and analogues thereof. The compounds of the present invention are selective estrogen receptor modulator, which can selectively activate ER? and simultaneously express high estrogenic activity, and also can be applied as medical or food compositions to improve estrogen deficiency-related symptoms.Type: GrantFiled: April 3, 2009Date of Patent: March 8, 2011Assignee: National Taiwan UniversityInventors: Ching-Jang Huang, Ssu-Ching Wang, Yueh-Hsiung Kuo, Yong-Han Hong, Bi-Fong Lin, Chin Hsu
-
Publication number: 20110046375Abstract: The present invention relates to ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylates and a process for the production thereof. Furthermore, the present invention relates to a process for the production of statins and in particular of Rosuvastatin and derivates thereof, wherein the above mentioned compounds are used as intermediates.Type: ApplicationFiled: January 20, 2009Publication date: February 24, 2011Applicant: LEK PHARMACEUTICALS D.D.Inventors: Jerome Cluzeau, Zdenko Casar, Peter Mrak, Matej Oslaj, Gregor Kopitar
-
Publication number: 20110034549Abstract: A compound of general formula (I) wherein A, Y, W, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.Type: ApplicationFiled: December 19, 2008Publication date: February 10, 2011Applicant: PHARMA MAR, S.A.Inventors: Alberto Rodriguez Vicente, María Garranzo García-Ibarrola, Carmen Murcia Pérez, Francisco Sánchez Sancho, Maria del Carmen Cuevas Marchante, Cristina Mateo Urbano, Isabel Digón Juárez
-
Patent number: 7868191Abstract: The present invention relates to methods for the preparation and purification of mupirocin calcium. The process comprises adsorbing mupirocin to a hydrophobic adsorbent resin, exposing the bound mupirocin to a calcium-containing solution, washing impurities from the resin and eluting purified mupirocin calcium from the resin.Type: GrantFiled: August 29, 2007Date of Patent: January 11, 2011Assignee: Xellia Pharmaceuticals ApSInventor: Lene Aassveen
-
Publication number: 20100311673Abstract: Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.Type: ApplicationFiled: August 18, 2010Publication date: December 9, 2010Inventors: Bryce Alden Harrison, Spencer David Kimball, Ross Mabon, David Brent Rawlins
-
Publication number: 20100305340Abstract: Three step process for obtaining liquid biofuels consisting mainly of isomers of methylpyran and methyl tetrahydropyran from cellulose, hemicelluloses or starch, using in a first step N alkyl imidazol chloride containing a slight excess of hydrochloric acid 37%. This mixture acts as a solvent and catalyst for dissolution and hydrolysis of cellulose and dehydration of glucose to isomers of hydroxymethyl pyranone (HMP). In a second step the reaction mixture is mixed with a water solution of sodium chloride to increase the ionic strength, and to make possible an extraction with butanol, which otherwise is miscible with the ionic liquid reaction mixture. Butanol was found to be the best solvent for HMP under these conditions. In a third step, the butanol extract is concentrated by distillation, and the concentrate is submitted to hydrogenation with gaseous hydrogen using palladium or platin catalysts on carbon or alumina. The final mixture is separated from butanol by distillation.Type: ApplicationFiled: June 2, 2009Publication date: December 2, 2010Inventor: Pedro Brito da Silva Correia
-
Publication number: 20100279872Abstract: Pyrandione, thiopyrandione and cyclohexanetrione compounds, which are suitable for use as herbicides.Type: ApplicationFiled: December 11, 2008Publication date: November 4, 2010Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Michel Muehlebach, Christopher John Mathews, James Nicholas Scutt, Stephane Andre Marie Jeanmart, Mangala Govenkar
-
Publication number: 20100222599Abstract: Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.Type: ApplicationFiled: August 21, 2009Publication date: September 2, 2010Inventors: Jason Liou, Yuelin Wu, Shengbin Li, Ge Xu
-
Publication number: 20100216915Abstract: The present invention is directed to ester derivatives of levulinic acid that are useful as plasticizers and/or coalescent solvents in polymer compositions, compositions comprising the ester derivatives, methods of making the derivatives and the compositions, and the use of the derivatives as additives in polymer compositions.Type: ApplicationFiled: January 22, 2007Publication date: August 26, 2010Applicant: Archer-Daniels-Midland CompanyInventor: Paul D. Bloom
-
4-PHENYL-PYRANE-3,5-DIONES,4-PHENYL-THIOPYRANE-3,6-DIONES AND CYCLOHEXANETRIONES AS NOVEL HERBICIDES
Publication number: 20100210466Abstract: Pyrandione, thiopyrandione and cyclohexanetrione compounds, which are suitable for use as herbicides.Type: ApplicationFiled: December 12, 2007Publication date: August 19, 2010Applicants: SYNGENTA PARTICIPATIONS AG, SYNGENTA LIMITEDInventors: Michel Muehlebach, Christoper John Matthews, James Nicholas Scutt, Mangala Govenkar -
Patent number: 7772378Abstract: Glucopyranosyl-substituted (hetero)arylethynyl-benzene derivatives of the general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.Type: GrantFiled: February 22, 2006Date of Patent: August 10, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Frank Himmelsbach, Matthias Eckhardt, Peter Eickelmann, Leo Thomas, Edward Leon Barsoumian
-
Publication number: 20100179191Abstract: Glucopyranosyl-substituted cyclopropyl-benzene derivatives defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.Type: ApplicationFiled: August 14, 2007Publication date: July 15, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Frank Himmelsbach, Matthias Eckhardt, Peter Eickelmann
-
Patent number: 7737287Abstract: This invention relates to combinatorial libraries of potentially biologically active mainly monosaccharide compounds and to methods of preparing same. These compounds are variously functionalized, with a view to varying lipid solubility, size, function and other properties, with the particular aim of discovering a drug or drug-like compound, or compounds with useful properties. The invention provides intermediates, processes and synthetic strategies for the solution or solid phase synthesis of monosaccharides, variously functionalized about the sugar ring, including the addition of aromaticity and charge, and the placement of amino acid and peptide side chain units of isosteres thereof.Type: GrantFiled: March 28, 2003Date of Patent: June 15, 2010Assignee: Alchemia LimitedInventors: Wim Meutermans, Michael Leo West, Thanh Le Giang, George Adamson, Karl Schafer, Giovanni Abbenante
-
Publication number: 20100144862Abstract: The invention relates to the use of substituted pyranone acid derivatives and of their physiologically acceptable salts for producing medicaments for treating the metabolic syndrome.Type: ApplicationFiled: July 16, 2009Publication date: June 10, 2010Applicant: SANOFI-AVENTISInventors: Harm BRUMMERHOP, Siegfried STENGELIN, Hubert HEUER, Susanne KILP, Andreas HERLING, Thomas KLABUNDE, Dieter KADEREIT, Matthias URMANN
-
Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism
Publication number: 20100137194Abstract: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.Type: ApplicationFiled: November 23, 2009Publication date: June 3, 2010Applicants: EASTERN MICHIGAN UNIVERSITYInventors: Daniel A. Lawrence, Cory Emal, Jacqueline Cale, Enming J. Su, Mark Warnock, Shih-Hon Li, Jeanne A. Cupp -
Patent number: 7728156Abstract: The invention includes a method of treating a solid acid catalyst. After exposing the catalyst to a mixture containing a sugar alcohol, the catalyst is washed with an organic solvent and is then exposed to a second reaction mixture. The invention includes a process for production of anhydrosugar alcohol. A solid acid catalyst is provided to convert sugar alcohol in a first sample to an anhydrosugar alcohol. The catalyst is then washed with an organic solvent and is subsequently utilized to expose a second sample. The invention includes a method for selective production of an anhydrosugar. A solid acid catalyst is provided within a reactor and anhydrosugar alcohol is formed by flowing a starting sugar alcohol into the reactor. The acid catalyst is then exposed to an organic solvent which allows a greater amount of additional anhydrosugar to be produced than would occur without exposing the acid catalyst to the organic solvent.Type: GrantFiled: January 26, 2006Date of Patent: June 1, 2010Assignee: Battelle Memorial InstituteInventors: Jianli Hu, Johnathan E. Holladay, Xinjie Zhang, Yong Wang
-
Publication number: 20100125102Abstract: The present invention relates to compounds having estrogenic activity selected from the group consisting of Loliolide, (4S,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one, (4R,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one and analogues thereof. The compounds of the present invention are selective estrogen receptor modulator, which can selectively activate ER? and simultaneously express high estrogenic activity, and also can be applied as medical or food compositions to improve estrogen deficiency-related symptoms.Type: ApplicationFiled: April 3, 2009Publication date: May 20, 2010Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Ching-Jang Huang, Ssu-Ching Wang, Yueh-Hsiung Kuo, Yong-Han Hong, Bi-Fong Lin, Chin Hsu
-
Publication number: 20100112482Abstract: A fluorinated monomer of cyclic acetal structure has formula (1) wherein R is a C1-C20 alkyl group which may be substituted with halogen or separated by oxygen or carbonyl, and Z is a divalent organic group which forms a ring with alkylenoxy and contains a polymerizable unsaturated group. A polymer derived from the fluorinated monomer may be endowed with appropriate water repellency, water sliding property, lipophilicity, acid lability and hydrolyzability and is useful in formulating a protective coating composition and a resist composition.Type: ApplicationFiled: October 29, 2009Publication date: May 6, 2010Inventors: Takeru WATANABE, Satoshi SHINACHI, Takeshi KINSHO, Koji HASEGAWA, Yuji HARADA, Jun HATAKEYAMA, Kazunori MAEDA, Tomohiro KOBAYASHI
-
Publication number: 20100098640Abstract: Provided herein are chelating agents and metal chelates that are useful in diagnostic and therapeutic applications. The uses of metal chelates provided herein include their use as contrast agents in medical imaging modalities, such as magnetic resonance imaging (MRI).Type: ApplicationFiled: June 20, 2006Publication date: April 22, 2010Inventors: Seth M. Cohen, David T. Puerta
-
Patent number: 7700783Abstract: Processes for synthesizing a compound of Formula (I) are provided by reacting a compound of Formula (i) with a compound of Formula (xx).Type: GrantFiled: October 12, 2004Date of Patent: April 20, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Amos B Smith, III, Brian Scott Freeze, Ming Xian
-
Publication number: 20100062486Abstract: The present invention provides a protein comprising the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3 (except for proteins of the amino acid sequences as shown in SEQ ID NOS: 4 to 6), and a process for industrially advantageously producing a compound that inhibits HMG-CoA reductase and has an action to decrease serum cholesterol, using DNA encoding the protein comprising the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3 (except for DNA encoding the protein comprising the amino acid sequence as shown in SEQ ID NO: 4).Type: ApplicationFiled: November 29, 2006Publication date: March 11, 2010Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Shin-ichi Hashimoto, Yoshiyuki Yonetani, Masaki Maeda
-
Publication number: 20100063141Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.Type: ApplicationFiled: July 15, 2009Publication date: March 11, 2010Applicant: Theracos, Inc.Inventors: Brian Seed, Binhua LV, Jacques Y. Roberge, Yuanwei Chen, Kun Peng, Jiajia Dong, Baihua Xu, Jiyan Du, Lili Zhang, Xinxing Tang, Ge Xu, Yan Feng, Min Xu
-
Publication number: 20100038588Abstract: A nematic liquid crystal compound represented by any one of formulas (a-1) to (a-6): in formulas (a-1) to (a-6), Ra and Rb are each independently hydrogen or alkyl having 1 to 10 carbons, provided that in the alkyl, —CH2- may be replaced by —O—, —(CH2)2- may be replaced by —CH?CH—, and hydrogen may be replaced by a halogen; ring A1 and ring A2 are each independently trans-1,4-cyclohexylene or 1,4-phenylene, provided that in these rings hydrogen may be replaced by a halogen, and in the case where the ring is trans-1,4-cyclohexylene, —CH2- may be replaced by —O—, and —CH2CH— may be replaced by —CH?C—; and Z1 and Z2 are each independently a single bond, —COO—, —OCO—, —OCH2-, —CH2O— or —CH2CH2-, provided that in formula (a-3), in the case where ring A2 is trans-1,4-cyclohexylene, Z2 is a single bond, —COO—, —OCO—, —OCH2- or —CH2O—, in the case where Ra is —C3H7, Rb is —OC2H5, and Z2 is a single bond, ring A2 is trans-1,4-cyclohexylene, 1,3-dioxane-2,5-diyl, 2-fluoro-1,4-phenylene, 3-fluoro-1,4-phenylene, 2-flType: ApplicationFiled: October 2, 2009Publication date: February 18, 2010Applicants: CHISSO CORPORATION, CHISSO PETROCHEMICAL CORPORATIONInventors: Mayumi GOTO, Teruyo SUGIURA, Norikatsu HATTORI
-
Patent number: 7662790Abstract: Glucopyranosyloxy-substituted (heteroaryloxy-benzyl)-benzene compounds of the general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.Type: GrantFiled: April 13, 2006Date of Patent: February 16, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Frank Himmelsbach, Matthias Eckhardt, Peter Eickelmann, Leo Thomas
-
Publication number: 20100029579Abstract: The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M2 protein bearing viruses. These compounds are also useful as inhibitors of the replication factors of hepatitis virus type C (HVC). The invention also describes pharmaceutical compositions containing the compounds of the invention either alone or in combination admixed with a suitable and pharmaceutically acceptable carrier.Type: ApplicationFiled: January 22, 2008Publication date: February 4, 2010Applicant: Therapicon SrlInventors: Paolo Alberto Veronesi, Pablo Eduardo Andres Rodriguez, Emanuela Peschechera, Susanna Lucia Veronesi
-
Publication number: 20100016249Abstract: Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy.Type: ApplicationFiled: December 6, 2006Publication date: January 21, 2010Applicant: National Cancer CenterInventors: Soo Youl Kim, Dae Seok Kim
-
Publication number: 20100016422Abstract: Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders.Type: ApplicationFiled: July 15, 2009Publication date: January 21, 2010Inventors: Susan Margaret De Paul, Anett Perlberg, Matthew Mangzhu Zhao
-
Patent number: 7649099Abstract: The invention includes methods of producing dianhydrosugars. A polyol is reacted in the presence of a first catalyst to form a monocyclic sugar. The monocyclic sugar is transferred to a second reactor where it is converted to a dianhydrosugar alcohol in the presence of a second catalyst. The invention includes a process of forming isosorbide. An initial reaction is conducted at a first temperature in the presence of a solid acid catalyst. The initial reaction involves reacting sorbitol to produce 1,4-sorbitan, 3,6-sorbitan, 2,5-mannitan and 2,5-iditan. Utilizing a second temperature, the 1,4-sorbitan and 3,6-sorbitan are converted to isosorbide. The invention includes a method of purifying isosorbide from a mixture containing isosorbide and at least one additional component. A first distillation removes a first portion of the isosorbide from the mixture. A second distillation is then conducted at a higher temperature to remove a second portion of isosorbide from the mixture.Type: GrantFiled: January 26, 2006Date of Patent: January 19, 2010Assignee: Battelle Memorial InstituteInventors: Johnathan E. Holladay, Jianli Hu, Yong Wang, Todd A. Werpy, Xinjie Zhang